Literature DB >> 24291553

Dose-to-dose variations with single packages of counterfeit medicines and adulterated dietary supplements as a potential source of false negatives and inaccurate health risk assessments.

B J Venhuis1, M E Zwaagstra2, P H J Keizers3, D de Kaste3.   

Abstract

In this report, we show three examples of how the variability in dose units in single packages of counterfeit medicines and adulterated dietary supplements may contribute to a false negative screening result and inaccurate health risk assessments. We describe a counterfeit Viagra 100mg blister pack and a box of an instant coffee both containing dose units with and without an active pharmaceutical ingredient (API). We also describe a purportedly herbal slimming product with capsules that mutually differed in API and impurities. The adulterated dietary supplements contained sibutramine, benzyl-sibutramine, N-desmethyl-sibutramine (DMS), N,N-didesmethyl-sibutramine (DDMS) and several other related impurities. Counterfeit medicines and adulterated dietary supplements are a health risk because their quality is unreliable. Health risks are even greater when such unreliability extends to fundamental differences between dose units in one package. Because dose-to-dose variability for these products is unpredictable, the confidence interval of a sample size is unknown. Consequently, the analyses of a selection of dose units may not be representative for the package. In the worst case, counterfeit or unauthorised medicines are not recognised as such or a health risk is not identified. In order to reduce erroneous results particular care should be taken when analysing a composite of dose units, when finding no API in a dietary supplement and when finding conformity in a suspect counterfeit medicine.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benzyl-sibutramine; Counterfeit medicines and adulterated dietary supplements; Dose-to-dose variability; Sibutramine analogues; UPLC-QTOF-MS/MS

Mesh:

Substances:

Year:  2013        PMID: 24291553     DOI: 10.1016/j.jpba.2013.10.038

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  A Repeat Random Survey of the Prevalence of Falsified and Substandard Antimalarials in the Lao PDR: A Change for the Better.

Authors:  Patricia Tabernero; Mayfong Mayxay; María Julia Culzoni; Prabha Dwivedi; Isabel Swamidoss; Elizabeth Louise Allan; Maniphone Khanthavong; Chindaphone Phonlavong; Chantala Vilayhong; Sengchanh Yeuchaixiong; Chanvilay Sichanh; Sivong Sengaloundeth; Harparkash Kaur; Facundo M Fernández; Michael D Green; Paul N Newton
Journal:  Am J Trop Med Hyg       Date:  2015-04-20       Impact factor: 2.345

2.  Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products.

Authors:  Manuela Pellegrinia; Maria Concetta Rotolo; Francesco Paolo Busardò; Roberta Pacifici; Simona Pichini
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

3.  The development and appraisal of a tool designed to find patients harmed by falsely labelled, falsified (counterfeit) medicines.

Authors:  Marija Anđelković; Einar Björnsson; Virgilio De Bono; Nenad Dikić; Katleen Devue; Daniel Ferlin; Miroslav Hanževački; Freyja Jónsdóttir; Mkrtich Shakaryan; Sabine Walser
Journal:  BMC Health Serv Res       Date:  2017-06-20       Impact factor: 2.655

Review 4.  Facing Counterfeit Medications in Sexual Medicine. A Systematic Scoping Review on Social Strategies and Technological Solutions.

Authors:  Andrea Sansone; Béatrice Cuzin; Emmanuele A Jannini
Journal:  Sex Med       Date:  2021-10-04       Impact factor: 2.491

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.